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Abstract
The objective of the present feasibility study was to transfer single cell line cells to either microscopy slides for down-
stream immune characterization or to polymerase chain reaction tubes for downstream DNA quantitation. Tumour cell
lines, SKBR3 and MCF7 and trophoblast cell line JEG-3 were spiked in healthy donor blood. The CytoTrack system was
used to scan the spiked blood samples to identify target cells. Individual target cells were identified, picked by use of a
CytoPicker and deposited to either a microscopic slide or a polymerase chain reaction tube (PCR). Single tumour cells
on microscopic slides were further immunostained with human epidermal growth factor receptor 2 (Her2) and epithelial
cell adhesion molecule (EpCAM). From the picked cells in polymerase chain reaction tubes, DNA was amplified, quanti-
fied and used for Short Tandem Repeat genotyping. Depositing rare cells to microscopy slides was laborious with only
five cells per hour. In this study with a trained operator, the picked cells had an 80.5% recovery rate. Depositing single
trophoblast cells in PCR tubes was a faster process with 10 cells in 5 min. Immunostaining of isolated cells by both Her2
and EpCAM was possible but showed varying staining intensity. Presence of trophoblasts and contaminating white blood
cells in PCR tubes after cell picking was confirmed based on DNA yield and mixed Short Tandem Repeat profiles in five
out of eight samples. Using the CytoPicker tool, single tumour and trophoblast cells were successfully isolated and
moved from blood samples, allowing subsequent immunostaining or Short Tandem Repeat genotyping.
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Introduction
Both circulating tumour cells (CTC) and foetal tro-
phoblasts are rare cells in the blood stream. Rare cells
are potential tools in precision medicine, and there is
an ongoing interest for understanding their phenoty-
pic and genotypic behaviour. A method to detect and
collect the rare cells from other blood cells would be a
valuable tool before further characterization. Single
cell analysis is plausible with analysis such as fluores-
cence in situ hybridization (FISH), polymerase chain
reaction (PCR), immunostains or massive parallel
sequencing.1
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From cancerous sites, tumour cells may spread
through the blood and lymphatic system to other parts
of the body.2–4 A blood sample containing CTC is
often referred to as a ‘liquid biopsy’ and may serve as a
surrogate for the metastatic tumour. The number of
CTC is prognostic, and specific CTC-related biomar-
kers may serve as additional diagnostic tools and reflect
the discrepancy between local metastatic sites.1,5,6 In
recent years, characterization of the human epidermal
growth factor receptor 2 (HER2) expression profile of
the primary tumour has been a success in the develop-
ment of precision medicine. Hence, immune targeting
of the receptor has prolonged survival and even
decreased mortality rates among HER2 positive
patients.7,8 Potentially, CTC HER2 expression profiles
may prove valuable and assist personalized medicine in
metastatic disease.9 Additional molecular targets in
CTC characterization, like epithelial cell adhesion
molecule (EpCAM), may also become future predictive
biomarkers, complying with the contemporary transi-
tion towards precision medicine.9,10
Other rare cells have potential to become valuable
diagnostic tools. The presence of foetal trophoblasts in
the peripheral blood stream of pregnant women has
been recognized for a few decades. The isolation of
those and down stream genetic analysis could become
key in cell-based non-invasive prenatal diagnosis.11
The CytoTrack procedure is a technique for rare cell
isolation where all nucleated cells in a blood sample are
scanned with the CytoTrack Scanner.12–16 The
CytoTrack system automatically detects immune
stained cells from blood samples smeared on a round
glass disc (CytoDisc) using fluorescence microscopy.
With the CytoPicker system, it is possible to manually
select the cells and extract them from the CytoDisc,
which opens the possibility of analysing individual
cells. We have previously shown that the CytoTrack
system is able to detect rare cells, like CTC, from a
blood sample.12–16 It is unknown if such rare cells can
be transferred from the CytoDisc to microscopy slides
and PCR tubes. The objective of the present feasibility
study was to transfer single cell line cells to either
microscopy slides for downstream HER2 and EpCAM
immune characterization or to PCR tubes for down-
stream DNA quantitation and human identification
Short Tandem Repeat (STR) genotyping.
Materials and methods
Cell cultures
For spiking experiments, the human breast cancer cell
lines MCF7 and SKBR3 and the human placenta chor-
iocarcinoma cell line JEG-3 were used (American Type
Culture Collection (ATCC), Manassas, VA, USA). The
MCF7, SKBR3 cancer-cells and JEG-3 trophoblast-cells
were cultured in Dulbecco’s modified Eagle’s medium-
GlutaMAX (Life Technologies, Carlsbad, CA, USA)
supplemented with 1% penicillin–streptomycin (Life
Technologies) and 10% heat-inactivated foetal bovine
serum (Life Technologies). All cell lines were grown in a
humidified atmosphere containing 5% CO2 at 37C.
Cells were washed with phosphate-buffered saline (PBS)
and harvested with trypsin–ethylenediaminetetraacetic
acid (EDTA) (0.25%) (Thermo Fisher Scientific,
Waltham, MA, USA).
Cells spiked in donor blood
Spiking was performed by adding 1million MCF7 or
SKBR3 cells into 7.5mL blood in CellSave preservative
tubes (Janssen Diagnostics, LLC, Raritan, NJ, USA). In
all, 100,000 JEG-3 cells were spiked into 9mL blood
sample in Greiner Vacuette tubes (Greiner Bio-One
GmbH, Germany). The blood tubes were immediately
processed. The blood was sampled from healthy donors
(Nordsjællands Hospital, Hillerød, Denmark, or Ghent
University, Belgium). A written informed consent in
accordance with the Declaration of Helsinki was
obtained from each participant before sample collection.
Staining of tumour cells
Spiked blood samples were prepared as previously
described.12–16 In brief, after centrifugation, the buffy
coat was isolated, and lysis buffer was added to clear
co-isolated erythrocytes. The cells were stained with CT
Reagent Kit A (CytoTrack, Lyngby, Denmark), con-
taining a nuclear stain (4#,6-diamidino-2-phenylindole
(DAPI)), stain of CD45 (APC) and pan-cytokeratin
(fluorescein isothiocyanate (FITC)). The stained sample
was smeared on a round glass disc, CytoDisc
(CytoTrack, Lyngby, Denmark), and left to dry.
Detection of tumour/trophoblast cells
Tumour cells and trophoblast cells were readily visible
in almost any field on the CytoDisc using ultra-
sensitive fluorescence scanner CytoTrack CT4
(CytoTrack, Lyngby, Denmark).12,14 To identify the
tumour cells in the samples, following established cri-
teria were applied: presence of blue nucleus (visible in
both DAPI/FITC and DAPI channels); presence of
green cytokeratin (visible in both DAPI/FITC and
FITC channels); and no presence of red CD45 (visible
in the APC channel). Morphological criteria were
nearly round and size was .4mm.5,17 Once identified,
the tumour/trophoblast cells were ready for cell picking.
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Cell-picking procedure
Cell-picking is a manual process using the CytoPicking
system added to the CytoTrack scanner CT4.
Cell deposition on microscopy slides
Pipette pressure was carefully increased to expulse the
cell on a microscopy slide. For deposition on micro-
scopy slides, 70% ethanol (CSS Healthcare AB,
Malmö, Sweden) was used as deposition media.
Continuous monitoring and careful regulation of the
pressure in the pipette was essential, so that cell posi-
tion after expulsion could be recorded. Cells were mon-
itored until the ethanol evaporated, since the cells
tended to move with the microflows that occurred as
the fluid evaporated. Coordinates of the cells as well as
images were recorded for the purpose of revisiting the
cells following the stains.14 Five cells were deposited on
each slide inside a small square (1.0 3 1.0 cm) carved
into the slides, which assisted in rediscovery of the cells
after deposition.
Single cell immune characterization – HER2 and
EpCAM
The deposited cells were stained by two different anti-
bodies: anti-human CD340 (HER2) (clone 24D2,
Alexa Fluor 647) and anti-EpCAM (clone VU-1D9,
Alexafluor 555). A volume of 30mL antibody solution
(in PBS, 1:50) was applied to the deposited cells and
incubated 1 h with a cover slide. It was followed by
wash in PBS and drying of the cells. All slides were
stained with HER2, and a small batch of these slides
was stained with EpCAM. The stains were scored by
fluorescence intensity of HER2 (Cy5 channel) and
EpCAM (PE channel). All scoring of stains were
blinded.
Cell depositing in PCR tubes
The deposition of cell-picked cells in PCR tubes was
performed in a similar fashion to deposition on micro-
scopy slides with minor alterations. Pipette pressure
was carefully increased to expulse the cell in a droplet
of PCR grade water in a PCR tube lid. The PCR tube
was closed and spun by microcentrifuge and stored at –
80C until whole genome amplification (WGA).
WGA and evaluation of DNA quantity and quality of
trophoblasts in Eppendorf tubes
Two WGA kits were used for downstream cell lysis
and DNA amplification after cell picking. For each
WGA method, two 3-cell samples and two single-cell
samples were deposited in a total volume of 1mL for
DOPlify reaction kit and 5mL for PicoPLEX WGA
kit, respectively.
Cell lysis and WGA was performed using DOPlify
reaction kit (Reproductive Health Science, Thebarton,
Australia) and PicoPLEX WGA kit (Rubicon
Genomics Inc., MI 48108, USA) according to manu-
facturer’s instructions. For both WGA methods, a pos-
itive control sample, containing 30pg high quality
control DNA (Human Genomic DNA, Roche, 100mg
(500mL)), was included to evaluate the DNA yield of
the WGA procedure in optimal conditions. Also, a neg-
ative control sample, containing 1mL PBS, was added
to determine possible contamination introduced during
WGA. Purification of the amplified samples was per-
formed using the Genomic DNA Clean &
Concentrator kit (version 1.0.0, Zymo Research,
Irvine, CA, USA) following manufacturer’s recommen-
dations. DNA yield was then determined using Qubit
dsDNA High Sensitivity Assay Kit (Life technolo-
gies, Carlsbad, CA, USA). DNA quality of all WGA
samples was evaluated by means of automated DNA
electrophoresis using Agilent High Sensitivity DNA kit
(Agilent Technologies, Santa Clara, CA, USA).
STR genotyping of cells in Eppendorf tubes
An in-house multiplex PCR assay, based on the
Promega Powerplex, was used to simultaneously
amplify the amelogin locus and 14 tetrameric STR loci
across the human genome: D3S1358, TH01, D21S11,
D18S51, vWA, D8S1179, TPOX, FGA, D5S818,
D13S317, SE33, CD4, D7S820 and D16S539. Each
reaction mix contained 2.5U Hotstar Taq polymerase
(Qiagen, Hilden, Germany), 0.5mM MgCl2 (Qiagen,
Hilden, Germany), 0.4mg/mL albumin (Sigma-Aldrich,
Saint Louis, USA), 13 PCR buffer (Qiagen, Hilden,
Germany), 0.15mM–1nM of each STR primer and
30mL of amplified DNA, with a total volume of 50mL.
All amplified DNA samples served as template. For
DOPlify samples, 1 ng WGA product was added
whereas for PicoPLEX samples, 5 ng was added.
Multiplex PCR consisted of three steps: an initial dena-
turation step (95C, 15min), 28 amplification steps
(94C, 1min; 58C, 1min; 72C, 1min 20 s) and a final
elongation step (72C, 10min) were performed in a
SimpliAmp Thermal Cycler (Life Technologies,
Carlsbad, USA). Four additional samples were
included in multiplex PCR. A positive control, contain-
ing 30 pg high quality DNA (Human Genomic DNA,
Roche, 100mg (500mL)), was included, to confirm the
good performance of the PCR reaction in optimal con-
ditions. A sample containing 30mL of H2O was
included as a non-template control. Bulk DNA samples
from the JEG-3 cell line and the blood donor were
amplified as well. STR profiles were generated by capil-
lary electrophoresis using the ABI 3130 Genetic
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Analyzer equipped with GeneMapper ID3 1.2 soft-
ware (Applied Biosystems, Carlsbad, CA, USA).
Allele peaks were indicated by maintaining a detection
threshold of 50RFU.
Statistics
To investigate a difference in the rate of cell loss
between the two cell-lines MCF7 or SKBR3 when cell
picking to microscopy slides, a chi-square test was
applied with a a-significance level at 0.05.
Results
The cell-picking procedure and cell deposition on
microscopy slides
A skilled operator, defined as more than 10h training in
the procedure, was able to successfully cell pick (Figures
1 and 2) 140 cells out of attempted 174 (80.5%, Table
1). The ‘lost cells’ were cells vacuumed into the pipette,
but not successfully deposited on the microscopy slide.
Most frequently (n=17), cell loss was caused by sudden
changes in the air pressure of the pipette, resulting in a
violent expulsion of the cell, which complicated rediscov-
ery. The second most common reason of cell loss
(n=13) was cells adhered to the surface of the pipette.
For a few cells (n=4), the reason for cell loss was
unknown. There was no significant difference in the rate
of cell loss between the cell lines SKBR3 and MCF7
(p=0.303, chi-square test). The average time for the
procedure was five cells per hour. Drying time varied
the most during cell-picking (median: 5:23, range: 0:57–
14:34min), and the rest of the process took approxi-
mately 5min per cell. Thus, total time to finish cell-
picking and deposit a cell varied from 6 to 20min. It
was not always possible to collect a ‘clean’ cell; for
example, leukocytes entered the pipette and were co-
deposited.
HER2 and EpCAM characterization
After cell-picking to the microscopy slide, the slides
were HER2 stained. Out of 140 cells, 123 cells were
rediscovered after HER2 staining (Table 2). There was
no difference in loss between tumour cell lines SKBR3
and MCF7 (p=0.8). An additional six cells were lost
during the subsequent EpCAM staining process.
Cells were scored according to criteria: no visible out-
put (score 0), weak visible output (score 1) and strong
visible output (score 2; Figure 3). The HER2 control
Figure 1. Cell-picking: The set up for isolating single cells from
a smear on a CytoDisc using a micropipette with an oil
containing tube connected to a pump managing suction in the
pipette (the Cytopicker with the CytoTrack). After a tumour
cell was located on the CytoDisc and selected for isolation, a
generous amount of distilled water was deposited around the
cell (e.g. 20 mL) to allow the Cytopicker system to manipulate
the cell to release it from the surface of the CytoDisc. Gentle
suction was applied to the micropipette to aspirate the cell. The
pressure in the pipette was equalized and removed from the
surface of the CytoDisc. The CytoDisc could now be
substituted with the desirable target for cell deposition, either a
separate microscopy slide, or PCR tube. The chosen target for
cell deposition created different requirements in the subsequent
cell deposition process.
Figure 2. After cell-picking, cells were deposited on
microscopy slides. The target cells were picked from a
CytoDisc, which was smeared with cells from a blood sample,
spiked with cells of the MCF7 or SKBR3 breast cancer cell lines.
For depositing on microscopy slides, the slides were positioned
on a separate CytoDisc at a known and fixed position. After
picking a single cell, the cell remained in the pipette, while the
microscope slide mounted on a CytoDisc inserted under the
microscope. For deposition on microscopy slides, 10 mL 70%
ethanol (CSS Healthcare AB) was used as deposition media. The
tip of the Cytopicker pipette with tumour cells was carefully
positioned into the ethanol droplet. The pipette was emptied
completely by creating a forceful pressure by the CytoPicker to
expulse the cells. Afterwards, the Cytopicker pipette was
examined in the microscope to confirm that no tumour cells
remained in the pipette. Cells were monitored until the ethanol
evaporated and a new cell was picked from the sample CytoDisc
and deposited at the same position on the microscopy slide. Five
cells were deposited on each slide inside a small square
(1.0 3 1.0 cm) carved into the slides, which assisted in
rediscovery of the cells after deposition.
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stains (HER2 stain of cells from the same cell-line batch
with no previous cell picking) were strongly positive
(score 2) in all cases for SKBR3 cells.18,19 However, cell-
picked SKBR3 cells were almost equally distributed
between the HER2 scores (score 0, 1 or 2; Figure 3(a)).
The MCF7 control stains were all negative (score
0).18,19 The cell-picked cells were negative (score 0)
except five cells, which were weakly stained (score 1;
Figure 3(b)).
SKBR3 control cells were weakly stained for
EpCAM (score 1).20 All the cell-picked SKBR3 cells
received a positive score with the majority receiving a
score of 1 (Figure 3(c)).
Cell deposition in PCR tubes
Depositing cells into PCR tubes (Figure 4) was faster
than depositing onto microscopy slides, because there
were no drying times for the cells deposited in the PCR
tubes. The effective worktime when cell-picking all the
cells for this part of the project amounted to 3 h for 84
cells to 18 tubes. A rate of about 10 cells being cell-
picked and deposited in 5min was achieved, when cell-
picking multiple cells into the same tube.
DNA yield after WGA
After WGA, the DNA yield of all samples was assessed
(Table 3). For both WGA methods, the DNA yield of
the positive control was similar to the one- and three-
cell samples from the respective WGA method. A negli-
gible amount of DNA is present in the negative controls
after WGA.
DNA quality after WGA
After WGA, the DNA quality of all samples was evalu-
ated based on size distribution of the DNA products.





Lost SKBR3 (n) Lost MCF7 (n) Success rate of
cell picking (%)
174 140 20 14 80.5





after HER2 stain (n)
Rediscovery rate





after EpCAM stain (n)
Rediscovery rate
after EpCAM stain (%)
SKBR3 85 76 89.4 28 22 78.6
MCF7 55 47 85.5 – – –
Total 140 123 87.9
HER2: human epidermal growth factor receptor 2; EpCAM: epithelial cell adhesion molecule.
Figure 3. Single cell analysis. The distribution of cells according to blinded evaluation of the immune stain scores: (a) distribution of
SKBR3 cells according to given score of the HER2 stain; (b) distribution of MCF7 cells according to given score of the HER2 stain
and (c) distribution of SKBR3 cells according to given score of the EpCAM stain.
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Samples amplified with the same WGA kit show a
similar DNA size distribution profile. DOPlify WGA
samples show an average DNA fragment size of
384 6 59bp while PicoPLEX WGA samples result in
an average DNA fragment size of 506 6 92bp. For
both WGA methods, an electropherogram is shown for
a one-cell sample in Figure 5 ((a) DOPlify WGA and
(b) PicoPLEX WGA, respectively).
STR profiles
Five out of eight samples show a mixed STR profile.
This means that for some loci, more than two alleles
are detected and thus the sample originates from more
Figure 4. After cell-picking, cells were deposited in Eppendorf
tubes. The target cells were picked from a CytoDisc, which was
smeared with cells from a blood sample, spiked with cells of the
JEG-3 cell line. For depositing in PCR tubes, the tubes were
positioned horizontally with the lid open, under the microscope.
To create a media to deposit the tumour cells in, a droplet of
PBS was deposited inside the Eppendorf tube using a regular
precision pipette (Biohit 0.5–10 mL pipette). The volume of PBS
used varied according to specifications given by the downstream
PCR requirements, varying from 2–5 mL. The tip of the
CytoPicker pipette with trophoblast cells was carefully
positioned into the PBS droplet. The pipette was emptied
completely by creating a forceful pressure by the CytoPicker to
expulse the cells. Afterwards, the Cytopicker pipette was
examined in the microscope to confirm that no trophoblasts
remained in the pipette.
Table 3. DNA concentration and DNA yield after DOPlify and PicoPLEX WGA.
WGA method Sample Concentration (ng/mL) DNA yield (ng) Mean yield (ng) Standard deviation (ng)
DOPlify reaction kit 1 cell 1 40.4 1252.4 1357.8 149.1
2 47.2 1463.2




PicoPLEX WGA kit 1 cell 1 60.0 1860.0 1404.3 644.5
2 30.6 948.6




WGA: whole genome amplification.
Figure 5. DNA quality of a one-cell sample illustrated by
electropherogram for (a) DOPlify WGA and (b) PicoPLEX WGA.
FU: arbitrary Fluorescence Units.
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than one individual. The comparison of the sample pro-
files with the WBC reference profile (Figure 6) demon-
strates that all samples showed 3–11 loci containing all
reference alleles, indicating that WBC were present in
all Eppendorf tubes. The other loci either showed allelic
dropouts or complete locus dropouts. Only few loci
contained all reference alleles of the JEG-3 cell line.
Apart from the alleles that the JEG-3 and WBC have
in common, three samples did not show any alleles cor-
responding with the JEG-3 cell line. In the other five
samples, three to seven alleles identifying the presence
of JEG-3 cells were detected.
Discussion
Individual rare nucleated cells spiked in blood were manu-
ally picked, and single cell downstream analysis was made
possible. After smearing the blood sample on a glass sur-
face (CytoDisc), target cells were successfully picked and
deposited either in a PCR tube or on a microscopy slide.
Figure 6. Examples of STR profiles. The amplified samples (top row) were compared with the reference STR profiles of both the
JEG-3 cell line (top panel, bottom row) and the blood donor (bottom panel, bottom row). This way, the presence of target JEG-3
cells or accidently picked white blood cells (WBC) in the Eppendorf tube was determined. Sample STR profiles are compared with
the reference JEG-3 profile and with the WBC reference profile. Loci that contain all alleles of the reference profile are labelled in
green. An orange square represents a heterozygous reference locus for which only one allele is found in the sample. Loci, for which
no reference alleles are present, are indicated in red. Five out of eight samples show a mixed STR profile. This means that for some
loci, more than two alleles are detected and thus the sample originates from more than one individual. The comparison of the
sample profiles with the WBC reference profile demonstrates that all samples showed 3 to 11 loci containing all reference alleles,
indicating that WBC were present in all Eppendorf tubes. The other loci either showed allelic dropouts or complete locus dropouts.
Only few loci contained all reference alleles of the JEG-3 cell line. Apart from the alleles that the JEG-3 and WBC have in common,
‘DOPlify 1-cell sample 2’, ‘PicoPLEX 1-cell sample 1’ and ‘PicoPLEX 3-cell sample 2’ did not show any alleles corresponding with the
JEG-3 cell line. In the other samples, three to seven alleles identifying the presence of JEG-3 cells were detected.
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Trophoblast cells were transferred into PCR tubes, where
the presence of cells was confirmed by WGA. The negligi-
ble amount of DNA in the negative control sample sug-
gested that the DNA yield of the samples originates from
the picked cells (Table 3). Spiked tumour cells were singu-
larly deposited on microscopy slides and characterized
with HER2 and EpCAM immune staining (Figures 2 and
3). There was no difference in the picking abilities between
the two tumour lines, MCF7 and SKBR3, which may
indicate that the method is feasible for other cell lines as
well as a liquid biopsy.
In this study, up to 1million nucleated cells were
transferred to donor blood samples. This does not
mimic clinical samples, where cells are more rare.
However, it is proof of concept of the CytoPicker
method. The CytoPicker method is an add-on tool to
the CytoTrack system. We have previously shown the
system’s capabilities to detect rare cells, like CTC.12–16
This study shows that detection of rare cells by the
CytoTrack scanner may be proceeded by the cell-
picking method. A clear limitation of this study is the
use of up to a million cells for spiking in a blood sam-
ple, where the spiked cells cannot be termed rare.
However, during the technical cell picking procedure,
only one or a few cells were visible in the microscope
and those exact cells were isolated and moved to either
microscope slide or PCR tube and the recovery reported
to be around 80% (Tables 1 and 2). So it is reasonable
to presume that the method is also feasible when cells
are rare in the sample. However, CTC and foetal tro-
phoblasts may have other capabilities than cell lines,
and thus may be harder to transfer, for instance, if they
stick more to the CytoDisc or the pipette.
Picking single cells manually requires extensive
training and patience. The most common cause of cell
loss was air in the pipette, which was often triggered by
improper operation of the pump. Second most com-
mon reason of lost cells were cells adhered to the pip-
ette, where cell size and accompanying leukocytes
increased the chances of this happening. Another issue
was improper pipette installation, or breakage, which
lead to cell loss as pressure in the pipette became hard
to manage. These were issues that potentially arose
with fatigue and time constraints, and therefore, cell-
picking sessions should not be too long.
Lu et al.21 also isolated and moved single cells with
cell-picking and transfer carried out semi-automatically
from droplets of cell-suspension. They, however, also
experienced difficulties with managing the pressure in
the pipette. They transferred one cell in 30 s to micro-
well devices with a success rate of 80.24% resulting in
167 cells in total.21 This is similar to the success rate
and transfer time to PCR tubes in our study with can-
cer cells from blood, where 10 target cells were picked
and deposited in PCR tubes in 5min. However, transfer
time was slower to microscopy slides, primarily due to
monitoring the cell drying, otherwise it sometimes dis-
appeared in microfluids. This step could be improved
with similar microwells as in Lu et al.’s21 study.
Another method for single cell isolation is the fully
automatized Cellselector (ALS, GmbH, Jena) in com-
bination with the CellSearch system with a cell-
picking rate of about 50 cells in 1–1.5 h.22
A combination of the CellSearch system to isolate
tumour cells from a blood sample and DEPArray for
automatic purification from white blood cells and
blood debris is one solution to purify tumour cells for
further single cell characterization. This combined
automated method has shown a success rate ranging
from 60% to 80%, which is similar to this study.23
The advantages of the CytoTrack system combined
with the manual CellPicker may be the ‘all-in-one’ sys-
tem. Few methods integrate rare cell identification and
single cell retrieval within a single system.
In three of eight samples, only WBC from the donor
were present; however, in the remaining five samples,
both JEG-3 cells and WBC were present; thus, tropho-
blast cells were not cleanly aspirated. The DNA quality
and quantity of the WGA was adequate by both the
Doplify and Picoplex methods as revealed by yield and
average DNA fragment size. However, overall quality
of STR profiles was intermediate, since many allele or
locus dropouts occurred. This could be due to the red
blood cell lysing solution, which contains formaldehyde
and may have hampered WGA.
In this study, some cells were lost in the immunos-
taining processes. A way to optimize this could be to
stain cells in a moisture chamber instead of using cover-
slides to keep the slides moist during PBS wash. The
results from the EpCAM stain of the SKBR3 cells show
a more consistent stain result than the HER2 stain. In
order to use HER2 immune characterization of CTCs
as a reliable biomarker, more optimization is needed.
After detection of single cells with the CytoTrack sys-
tem, we have shown that these cells can be picked from
the CytoDisc and may be characterized for specific bio-
markers or genome sequencing. These preliminary results
show the possibilities with the manual Cytopicker.
Purifying single cells from patient blood samples pro-
ceeded by downstream characterization could help eluci-
date mechanisms of rare cells, and may predict disease
progression and be a tool in precision medicine.
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